RxDoctor Payments Data

Jill Richmond

Family · Louisa, VANPI 1922674662

Payments from drug & device makers

$1,485in general payments, 2019–2025

Across 76 payments — averaging $19.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$398
  • Amgen$245
  • Novo Nordisk$226
  • Pfizer$124
  • AbbVie$116
  • Lilly USA, LLC$97
  • plus $280 from 8 others

What the payments were for

  • Food & beverage$1,485100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,485 in reported general payments places this provider in the 75th percentile of 4,332 family providers in Virginia.

See all family providers in Virginia

Medicare billing

Part B allowed, 2024
$5,872
Medicare patients
52
Services billed
133

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RybelsusSemaglutide32$31,374
OzempicSemaglutide24$28,137
JanuviaSitagliptin Phosphate30$26,500
FarxigaDapagliflozin Propanediol17$19,659
EliquisApixaban16$15,731
TrulicityDulaglutide15$14,659
JardianceEmpagliflozin13$12,778
Spiriva HandihalerTiotropium Bromide12$12,042
Breztri AerosphereBudesonide/Glycopyr/Formoterol15$11,997
Breo ElliptaFluticasone/Vilanterol25$9,888
Albuterol Sulfate HfaAlbuterol Sulfate79$2,263
Rosuvastatin Calcium144$2,197
Oxybutynin Chloride22$2,098
Potassium Chloride32$1,952
Lantus SolostarInsulin Glargine,hum.Rec.Anlog11$1,459

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Ozempic$226$59,51156 claims
AstraZenecaFarxiga, Breztri Aerosphere$398$31,65632 claims
MerckJanuvia$47$26,50030 claims
PfizerEliquis$124$15,73116 claims
Lilly USA, LLCTrulicity$97$14,65915 claims
Boehringer IngelheimJardiance$38$12,77813 claims
GSKBreo Ellipta$34$9,88825 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,332 family providers in Virginia.

Other family in Louisa

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →